
Results 1 - 2 of 2 in Hypogonadism
FDA taking more time to review Endo drug
Endo Pharmaceuticals said Wednesday it was informed by the Food and Drug Administration that the agency has extended by three months its review of the company's new drug application for a hypogonadism treatment. Comment?
FDA Extends Review of Endo's Testosterone Drug Candidate by 3 Months
... for more data about the drug. The drug is a long-acting testosterone undecanoate injection intended to treat hypogonadism, which is a hormonal condition that interferes with the functioning of the testes. The injection is sold outside the U.S. as ... Comment?